Details

Drug Discovery for Leishmaniasis


Drug Discovery for Leishmaniasis


ISSN 1. Aufl.

von: Luis Rivas, Carmen Gil

199,99 €

Verlag: Royal Society Of Chemistry
Format: PDF
Veröffentl.: 26.10.2017
ISBN/EAN: 9781788010177
Sprache: englisch
Anzahl Seiten: 402

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

<p>For human health, leishmaniasis is among the most important protozoan diseases, superseded only by malaria. Globally, 10 to 12 million people are infected with 1.5 million new cases every year. The development of cheaper new drugs is urgently needed for this neglected disease that is developing resistance to current treatments. Chemotherapy remains the only treatment option for the bulk of patients. However, this is largely unaffordable for most. In the past three years numerous advances in drug discovery have been made for treating this disease by exploiting diverging metabolic pathways between the <em>Leishmania</em> enzymes and their hosts, using nanotechnology to target the immune cell phagolysosomes where <em>Leishmania</em> resides.</p>
<p><strong>Drug Discovery for Leishmaniasis</strong> aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in <em>Leishmania</em>.</p>
<p>Recent studies have shown that leishmaniasis affects some of the poorest people in the world, with 95% of fatal cases occurring in only 6 countries. With the WHO goal of eliminating this public health problem in the South-east Asia Region by 2020, this book will be important for anyone who is interested in neglected tropical diseases.</p>
<strong>Drug Discovery for Leishmaniasis</strong> aims to provide a perspective of the current treatments and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in
<em>Leishmania</em>.
Leishmaniasis, Impact and Therapeutic Needs; Anti-leishmanial Drug Discovery: Past, Present and Future Perspectives; From Bench to Bedside: Development and Optimization of Clinical Therapies for Visceral Leishmaniasis; Drug Assay Methodology in Leishmaniasis: From the Microplate to Image Analysis; The Pursuit of Novel Anti-leishmanial Agents by High-throughput Screening (HTS) of Chemical Libraries; Omics and Their Impact on the Development of Chemotherapy Against Leishmania; In silico Tools for Target Identification and Drug Molecular Docking in Leishmania; Medicinal Chemistry Strategies to Discover New Leishmanicidal Drugs; Natural Products as a Source of New Drugs Against Leishmania; Organometallic Compounds in Chemotherapy Against Leishmania; New Avenues for Drug Delivery in Leishmania: Using Treatment of Visceral Leishmaniasis with Amphotericin B as an Exemplar; Addressing the Molecular Biology of Leishmania for Drug Development; The Physical Matrix of the Plasma Membrane as a Target: The Charm of Drugs with Low Specificity; Nutrient Transport and Sensing as Pharmacological Targets for Leishmaniasis; Carbon Metabolism as a Drug Target in Leishmania; The Redox Metabolism and Oxidative Stress in Leishmania as a Crossroads for the Lethal Effect of Drugs; DNA Topoisomerases as Promising Targets for Leishmania Chemotherapy; Molecular Basis of Drug Resistance in Leishmania; The Macrophage–Parasite Interface as a Chemotherapeutic Target in Leishmaniasis

Diese Produkte könnten Sie auch interessieren:

Frontline and Factory
Frontline and Factory
von: Roy MacLeod, Jeffrey A. Johnson
PDF ebook
171,19 €